Cancer combination chemotherapy with retinoids: Experimental rationale

Leukemia

Volumn 8, Issue 9, 1994, Pages 1453-1457

  Bollag, W ^a   Majewski, Slavomir ^b   Jablonska, Stefanie ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIMITOTIC AGENT; BETA INTERFERON; CALCITRIOL; CYTOKINE; EPIDERMAL GROWTH FACTOR; ETRETIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 4; RETINOIC ACID DERIVATIVE; RETINOID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D DERIVATIVE;

ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CALCIUM METABOLISM; CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG POTENTIATION; EPITHELIUM CELL; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR VASCULARIZATION;

EID: 0028122260     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (41)

1. 3 and analogs. J Cell Biochem 1994 (in press).
2. Bollag W, Peck R. Modulation of growth and differentiation by combined retinoids and cytokines. In: Hong WK, Lotan R, eds, Retinoids in oncology, New York: Marcel Dekker, 1993;89-108.
3. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992;10:839-864.
4. Breitman TR, Keene BR, Hemmi H. Retinoic acid-induced differentiation of fresh human leukemia cells and the human myelomonocytic leukemia cell lines, HL-60, U937 and THP-1. Cancer Surv 1983;2:263-291.
5. Warrell RP, De Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. New Engl J Med 1993;329:177-189.
6. Peck R, Bollag W. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer 1991;27:53-57.
7. 3 induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor mediated maturation to macrophage-like cells. J Cell Biol 1984;98:391-398.
8. Olsson I, Gullberg U, Ivhed I, Nilsson K. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1α,25-dihydroxycholecalciferol. Cancer Res 1983;43:5862-5867.
9. 3: differential effects on leukemic cell growth, differentiation and intestinal calcium absorption. Cancer Res 1990; 50:6857-6864.
10. Bollag W, Peck R, Frey JR. Inhibition of proliferation by retinoids, cytokines and their combination in four human transformed epithelial cell lines. Cancer Lett 1992;62:167-172.
11. 3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem 1986;24:373-376.
12. Cross HS, Pavelka M, Slavik J, Peterlik M. Growth control of human colon cancer cells by vitamin D and calcium in vitro. J Natl Cancer Inst 1992;84:1355-1357.
13. Frampton RJ, Omond SO, Eisman JA. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D, metabolites. Cancer Res 1983;43:4443-4447.
14. 3 and the regulation of human cancer cell replication. Proc Soc Exp Biol Med 1989;191:221-226.
15. Colston KW, Chander SK, Mackay AG, Coombes RC. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992;44:693-702.
16. 3 and two synthetic analogs: relation to in vitro hypercalcemic potential. Naunyn-Schmiedeberg's Arch Pharmacol 1993;347:105-110.
17. 3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation. J Steroid Biochem Molec Biol 1991;39:455-461.
18. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1971;175:409-416.
19. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
20. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
21. Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120-1124.
22. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-146.
23. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic value of tumor vascularity in intermediate-thickness (0.76-4.0 thick) skin melanomas. Am J Pathol 1988;133:419-423.
24. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
25. Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988;59:44-51.
26. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992;3:89-96.
27. Majewski S, Polakowski I, Marczak M, Jablonska S. The effects of retinoids on lymphocyte- and transformed cell line-induced angiogenesis. Clin Exp Dermatol 1986;2:317-318.
28. Oikawa T, Hirotani K, Nakamura O, Shudo K, Hiragun A, Iwaguchi T. A highly antiangiogenic activity of retinoids. Cancer Lett 1989;48:157-162.
29. Rudnicka L, Marczak M, Szmurlo A, Makiela B, Skiendzielewska A, Skopinska M, Majewski S, Jablonska S. Acitretin decreases tumor cell-induced angiogenesis. Skin Pharmacol 1991;4:150-153.
30. Szmurlo A, Marczak M, Jablonska S, Bollag W. Antitumor action of retinoids: inhibition of tumor cell line-induced angiogenesis and prevention of tumors in mice. Dermatology 1992;184:116-119.
31. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-5161.
32. 3 analogues. Eur J Pharmacol 1990;178:247-250.
33. Majewski S, Kaminski MJ, Szmurlo A, Kaminska G, Malejczik J. Inhibition of tumor-induced angiogenesis by systemically administered protamine sulphate. Int J Cancer 1984;33:831-833.
34. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C. 9-cis retinoic acid is a high-affinity ligand for the retinoid X receptor. Cell 1992;68:397-406.
35. Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, Speck J, Kratzeisen C, Rosenberger M, Lovey A, Grippo JF. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature 1992;355:359-361.
36. 3 and their combination. Cancer Lett 1993; 75:35-39.
37. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W. Synergistic effect of retinoids and interferon α on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor cell lines. Int J Cancer 1994;57:81-85.
38. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E, Krakoff IH. 13-cis retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992;84:241-245.
39. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU, Hong WK. 13-cis retinoic acid and interferon α-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-241.
40. 3 signalling. Nature 1992;355:446-449.
41. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W. Two nuclear signalling pathways for vitamin D. Nature 1993;361:657-660.